NYSE: RFL · Life Sciences · 4 alerts · CIK 1713863
Share price
$0.9701Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Rafael Holdings, Inc. filings on SEC EDGAR ↗
Rafael Holdings filed a formal investor presentation deck (Exhibit 99.1) following its October 2026 NDA submission for remibetadex. The presentation highlights topline Phase 3 data in Niemann-Pick Disease Type C (NPC), including a prespecified analysis showing a 71% relative slowing of disease progression in a specific patient subgroup.
Rafael Holdings, Inc. faces substantial doubt regarding its ability to continue as a going concern, holding $22.1 million in cash as of July 31, 2026. The company recently submitted an NDA for Trappsol® Cyclo™ following a Phase 3 trial that failed its primary endpoint in the overall population but showed statistical significance in a prespecified subgroup.
Rafael Holdings reported its fourth quarter and full fiscal year 2026 results, highlighted by a net loss of $29.6 million for the year. The company also announced that its subsidiary, Cyclo Therapeutics, submitted a New Drug Application to the FDA for remibetadex to treat Niemann-Pick Disease Type C.